Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Trial in Early COVID-19, Assessing Use of Camostat by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion.

NCT04455815 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.

NCT NCT04455815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04455815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Trial in Early COVID-19, Assessing Use of Camostat by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion.
Lead sponsor
Cancer Research UK
Phase
Phase 2
Overall status
Terminated
Start date
September 23, 2020
Completion date
March 3, 2022
Enrollment
34 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 infection